Collegium Pharma (NASDAQ: COLL) reported Q2 EPS of $1.79, $1.43 better than the analyst estimate of $0.36. Revenue for the quarter came in at $82.9 million versus the consensus estimate of $84.77 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.